US Patent

US9694025 — Cyclic boronic acid ester derivatives and therapeutic uses thereof

Method of Use · Assigned to Rempex Pharmaceuticals Inc · Expires 2031-08-08 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects cyclic boronic acid ester derivatives and their use as therapeutic agents.

USPTO Abstract

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Drugs covered by this patent

Merrem (Meropenem) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2120`	—	Merrem

Patent Metadata

Patent number: US9694025
Jurisdiction: US
Classification: Method of Use
Expires: 2031-08-08
Drug substance claim: No
Drug product claim: No
Assignee: Rempex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.